STERIS Plc (Ireland)

As of October 3, 2025, STERIS Plc's technical trend is mildly bullish, supported by positive MACD and KST indicators, though it has underperformed the S&P 500 recently while outperforming it year-to-date, indicating mixed signals that suggest caution.

As of October 3, 2025, STERIS Plc's technical trend is mildly bullish, supported by positive MACD and KST indicators, though it has underperformed the S&P 500 recently while outperforming year-to-date.

As of September 4, 2025, STERIS Plc's technical trend is bullish, supported by strong indicators like bullish MACD readings and moving averages, with a year-to-date return of 21.86%, outperforming the S&P 500's 12.22%.

As of August 7, 2025, STERIS Plc is considered overvalued with a P/E ratio of 34, an EV to EBITDA ratio of 17.51, and a PEG ratio of 1.28, despite recent strong performance, as its long-term returns lag behind the S&P 500.

As of May 14, 2025, STERIS Plc is considered overvalued with a high P/E ratio of 34 compared to the peer average of 32.29, an EV to EBITDA ratio of 25.84 versus 16.95, and a lagging stock performance of -2.51% over the past month, indicating a shift from very expensive to expensive valuation.

As of June 17, 2025, the technical trend is bullish, supported by strong MACD and moving averages, despite some mixed signals from the KST and Dow Theory.

As of March 2022, the management team of STERIS Plc (Ireland) includes Dr. Mohsen Sohi (Independent Chairman), Mr. Walter Rosebrough (President and CEO), and several independent directors: Mr. Richard Breeden, Ms. Cynthia Feldmann, Dr. Jacqueline Kosecoff, Mr. Christopher Holland, and Mr. David Lewis.

STERIS Plc (Ireland) provides infection prevention and procedural products and services in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1.481 billion and a net profit of $147 million, with a market cap of approximately $23.32 billion.

As of Jun 18, STERIS Plc (Ireland) has a market capitalization of 23,321.79 million, with net sales of 5,459.51 million and a net profit of 611.56 million reported for the latest four quarters.